Omeros | OMER - Pre Tax Profit


Omeros reported $-65.12M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Adma Biologics USD 61.59M 14.07M Dec/2025
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -162.1M 164.84M Mar/2026
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 571K 8.95M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Rockwell Medical USD 343K 2.07M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
United Therapeutics USD 444M 6M Dec/2025
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xoma USD 15.98M 24.58M Jun/2024